Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma

(MedPage Today) -- PARIS--Neoadjuvant therapy with cemiplimab (Libtayo) achieved deep pathologic responses in patients with resectable cutaneous squamous cell carcinoma (cSCC), according to research presented here.
Among 79 patients treated...